PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩100 per share · Prices as of the 2026-10-02 close
Revenue has climbed past the mid-1-trillion-won mark, but operating margin remains in the low single digits, making the pace of new Samdasoo distribution and ophthalmology/rare-disease ETC pipeline commercialization the key variable for future profitability.
2025 consolidated revenue reached KRW 1.6595 trillion with operating profit of KRW 31.0 billion, an operating margin of 1.9%, showing thin margins relative to sales scale.
From January 2026, the Jeju Samdasoo distribution deal moved into a new four-year contract (through 2029) that expanded coverage to include large discount stores and supermarket chains.
Licensed-in pipeline assets such as the presbyopia treatment Ubagi (FDA approval) and the Fabry disease therapy Elfabrio (Korean approval) have entered the commercialization stage.
Quarterly net income attributable to owners swung sharply, from KRW 10.6 billion in Q3 2025 to KRW 3.9 billion in Q4 2025, reflecting one-off items such as impairment charges.
The debt ratio rose from 70.4% in 2022 to 85.5% in 2025, even as operating cash flow improved to KRW 82.3 billion in 2025.
Kwangdong Pharmaceutical is a diversified pharmaceutical and healthcare company whose revenue base spans product distribution (Samdasoo bottled water, vaccines), hospital sales of prescription drugs (ETC), OTC and health-supplement products, and other merchandise.
A substantial share of revenue comes from Jeju Samdasoo, the bottled water distributed on behalf of the Jeju Provincial Development Corporation, which reportedly accounts for over 30% of total sales.
Samdasoo holds roughly 40% share as the No.1 brand in Korea's bottled water market, and Samdasoo-related sales account for more than 30% of Kwangdong's total revenue, around KRW 320 billion.
The hospital-sales division carries products such as the shingles vaccine Shingrix and the breast cancer drug Lenara; this segment posted KRW 182.4 billion in sales last year, up 5.9%, with Shingrix and Lenara growing 48.2% and 14.5% to KRW 22.5 billion and KRW 13.3 billion respectively.
The "other products" category includes OTC items and health supplements such as Heotgae tea and Vita500 along with various imported products; top-line growth was attributed to strong sales in this category, which rose 24.3% year-on-year to KRW 241.9 billion.
More recently the company has been expanding an ophthalmology- and rare-disease-focused ETC portfolio through in-licensing, with the Fabry disease treatment Elfabrio and the alpha-mannosidosis therapy Lamzede both receiving Korean regulatory approval this year, both introduced under a 2023 exclusive distribution deal with Italy's Chiesi.
On vaccines, the company signed a co-marketing and distribution deal with MSD Korea for the adult 21-valent pneumococcal conjugate vaccine Capvaxive, adding to its existing Gardasil/Gardasil 9 and Shingrix portfolio.
Competitively, the distribution business faces large food and consumer-goods companies while the ETC business competes against major domestic pharmaceutical firms. The company is run under a co-CEO structure of Chairman Choi Seong-won and President Park Sang-young.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩425.3B | ₩4.5B | 1.1% |
| 2025Q3 | ₩444.5B | ₩10.9B | 2.4% |
| 2025Q4 | ₩412.1B | ₩12.3B | 3.0% |
| 2026Q1 | ₩410.9B | ₩7.5B | 1.8% |
| 2026Q2 | ₩439.8B | ₩2.8B | 0.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩1.4T | ₩38.2B | ₩24.2B | 2.7% | 4.7% | 70.4% |
| 2023 | ₩1.5T | ₩42.1B | ₩37B | 2.8% | 6.8% | 83.3% |
| 2024 | ₩1.6T | ₩30.1B | ₩40.5B | 1.8% | 7.0% | 89.3% |
| 2025 | ₩1.7T | ₩31B | ₩21B | 1.9% | 3.2% | 85.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
2025 consolidated revenue rose to KRW 1.6595 trillion, up from KRW 1.4315 trillion in 2022 over three consecutive years of growth, but operating profit of KRW 31.0 billion actually fell short of 2023's KRW 42.1 billion, pushing the operating margin down from 2.8% in 2023 to 1.9% in 2025.
Net income attributable to owners also declined from KRW 40.5 billion in 2024 to KRW 21.0 billion in 2025; on a standalone-filing basis the company attributed the decline to an impairment loss on investments in subsidiaries, which reduced net income.
Indeed standalone 2025 revenue grew 3.7% and operating profit rose 8.9% year-on-year, while net income over the same period fell 10.8%, a diverging pattern between operating and bottom-line results.
Quarterly figures show wide swings, with net income attributable to owners surging to KRW 10.6 billion in Q3 2025 before dropping back to KRW 3.9 billion in Q4 2025. Into 2026, operating profit narrowed from KRW 7.5 billion in Q1 to KRW 2.8 billion in Q2, suggesting no clear margin improvement has materialized yet.
Net income attributable to owners over the trailing four quarters (Q3 2025–Q2 2026) totaled roughly KRW 21.6 billion, well below annualizing the earlier peak quarters.
On cash flow, operating cash flow improved markedly to KRW 82.3 billion in 2025 from negative levels in 2023 and 2024 (-KRW 11.7 billion and -KRW 12.2 billion respectively), which appears linked to successful cost control that cut selling, general and administrative expenses by 0.3% year-on-year. The debt ratio rose from 70.4% in 2022 to 85.5% in 2025, indicating somewhat greater financial leverage.
In Korea's bottled water market, Jeju Samdasoo maintains a dominant No.1 position; Jeju Samdasoo holds roughly 40% market share, retaining an overwhelming lead in Korea's bottled water market.
Kwangdong Pharmaceutical has secured its market position as the exclusive distributor of Samdasoo outside Jeju Island, although analysts have pointed to a low-margin structure in food-related businesses including Samdasoo as a factor behind declining operating profit and unclear profitability.
Growth in the category has not always been steady either, as Jeju Provincial Development Corporation's Samdasoo sales volume once fell 3.5% year-on-year.
In the ETC segment, the ophthalmology and rare-disease treatment market is expanding, with the global myopia/presbyopia treatment market projected to grow from USD 22.6 billion in 2025 to USD 33.5 billion by 2030.
Across Korea's pharmaceutical industry, competition to secure in-licensing rights for promising multinational drug candidates has intensified, and Kwangdong has signed numerous such deals.
Industry observers note that the in-licensing strategy phase is largely complete, and the next stage is demonstrating commercialization results, with the key question being whether approved products can translate into actual prescriptions and sales.
Competition around Samdasoo's distribution rights has also been fierce, as eleven companies including Dong Wha Pharmaceutical, Pulmuone Foods, Binggrae, and Woongjin Foods competed for the distribution contract.
From January 2026, under the new four-year distribution agreement (2026-2029) with the Jeju Provincial Development Corporation, Kwangdong will supply and sell Jeju Samdasoo through nationwide (excluding Jeju Island) offline and online channels including large discount stores, convenience stores, supermarket chains, Hanaro Mart, online malls and B2B.
Notably, large discount store and supermarket chain distribution also transfers to Kwangdong starting next year, meaning the company will handle roughly 90% of Samdasoo's volume including convenience stores, Hanaro Mart and wholesale/retail agencies, which industry observers expect will broaden the related distribution revenue base.
In ophthalmology ETC, Ubagi, which received US FDA approval in February, is still undergoing Korean regulatory review, with no confirmed completion date.
In rare diseases, the company obtained Korean regulatory approval for the Fabry disease therapy Elfabrio from the Ministry of Food and Drug Safety, though national health insurance reimbursement listing remains a hurdle for Elfabrio to be adopted in clinical practice despite the approval.
The alpha-mannosidosis therapy Lamzede was also approved alongside, and the company has secured domestic rights for additional rare-disease treatments including Raxone, Mycapssa, Voxzogo, Myalept and Setmelanotide.
Management has stated a policy of treating 2026 as a key turning point when synergies from the Gwacheon headquarters relocation materialize, aiming to create business opportunities that generate both growth and profitability/future value simultaneously.
Ultimately, industry attention is focused on whether these in-licensed products can translate commercialization into actual prescriptions and sales, thereby driving a shift in the earnings structure.
Over roughly the past year, the price-earnings ratio observed in the market has ranged from around the mid-14x level to near 19x depending on the point in time. The price-to-book ratio has tended to trade at a discount to net asset value, with the share price frequently sitting below book value.
The dividend yield runs below the sector average, and dividend policy could vary with cash-flow conditions.
While the company has maintained profitability over the past three years, the persistently low operating margin means the market tends to view the pace of pipeline commercialization and the revenue contribution from the new Samdasoo contract as key variables for valuation.
Given the considerable volatility in quarterly results, some observers caution against drawing firm trend conclusions from any single quarter.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
The new four-year contract starting 2026 expanded distribution coverage to include large discount stores, convenience stores, supermarket chains, Hanaro Mart, online malls and B2B channels. With Kwangdong now handling 90% of Samdasoo's total volume, the product distribution revenue base has widened considerably. The expansion of this stable cash-generating distribution business is viewed as a positive factor.
Multiple in-licensed products—Ubagi (presbyopia), Elfabrio (Fabry disease), and Capvaxive (pneumococcal vaccine)—have entered the approval/commercialization stage.
These are higher-margin prescription products compared to distribution goods, and the company is expanding into ophthalmology- and rare-disease-focused ETC business, accelerating a shift in its profit structure. Translating this into actual prescription volumes, however, will take time.
2025 operating cash flow of KRW 82.3 billion marked a clear improvement from negative levels in 2023-2024. This appears linked to successful cost control that reduced SG&A expenses by 0.3% year-on-year. The improved cash generation could support future funding needs, including additional licensing deals.
The 2025 consolidated operating margin stood at just 1.87%, with profitability remaining low relative to the scale of revenue.
Analysts note that consolidated revenue includes a distribution-heavy MRO business and a high proportion of externally sourced products such as Samdasoo and vaccines, which inherently constrains margins. This is a structural feature where top-line growth does not automatically translate into profit growth.
2025 standalone net income fell 10.8% year-on-year due to an impairment loss on investments in subsidiaries. Quarterly figures also swung sharply, from KRW 10.6 billion in Q3 2025 to KRW 3.9 billion in Q4 2025. This volatility complicates efforts to gauge underlying earnings trends.
The debt ratio rose from 70.4% in 2022 to 85.5% in 2025 over three consecutive years. Greater leverage could translate into higher financing costs going forward. The rising ratio of liabilities to equity warrants attention from a financial-stability standpoint.
A significant portion of revenue depends on low-margin distribution products such as Samdasoo and vaccines, so a delayed shift toward ETC could slow margin improvement. Because the distribution contract is re-tendered every four years, there is a longer-term risk that contract terms could change.
High dependence on specific distribution products leaves the business exposed to shifts in negotiating leverage.
Elfabrio has obtained Korean approval, but national health insurance reimbursement listing remains a hurdle. Ubagi, separately from its US approval, is still undergoing Korean regulatory review with no confirmed completion timeline. Delays in approval or reimbursement listing remain a risk that could postpone commercialization.
In the bottled water market, competition has intensified as multiple companies including Dong Wha Pharmaceutical, Pulmuone Foods, Binggrae, and Woongjin Foods have competed for distribution rights.
There have been periods when Samdasoo's own sales volume fell 3.5% year-on-year, so market growth may not always be steady. The potential for heightened competition in future re-tenders also remains a latent risk.
The Q3 2026 earnings release is expected around this time — a chance to check whether the first-year effect of the expanded Samdasoo distribution and any ETC revenue contribution show up in the results.
Watch for Korean regulatory approval status of Ubagi — if approved, it could mark the start of ophthalmology ETC revenue contribution.
Monitor whether Elfabrio and Lamzede achieve national health insurance reimbursement listing — this step is necessary for meaningful revenue contribution.
The full-year 2026 (including Q4) earnings release will show the first full-year revenue and profit contribution from the new Samdasoo contract.
Kwangdong Pharmaceutical has steadily grown its revenue base, yet operating margin remains in the low single digits, leaving the gap between scale and profitability as the central challenge.
The new four-year Samdasoo contract starting in 2026 broadens the distribution revenue base, though it is also flagged as a low-margin structure.
The ophthalmology- and rare-disease-focused ETC pipeline—including Ubagi and Elfabrio—is still in the early stages of commercialization, and the pace at which these translate into actual prescriptions and sales will be a key variable for future results.
Quarterly net income has shown considerable volatility driven by one-off items such as impairment charges, making it difficult to draw firm conclusions from any single quarter. On the balance sheet, the debt ratio has trended higher even as operating cash flow has improved, presenting mixed signals.
Investors following this name will want to track the execution of the Samdasoo contract, the progress of ETC product approvals and reimbursement listings, and quarterly margin trends together.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.